![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TRAF3IP3 |
Gene summary for TRAF3IP3 |
![]() |
Gene information | Species | Human | Gene symbol | TRAF3IP3 | Gene ID | 80342 |
Gene name | TRAF3 interacting protein 3 | |
Gene Alias | T3JAM | |
Cytomap | 1q32.2 | |
Gene Type | protein-coding | GO ID | GO:0000139 | UniProtAcc | B1AJU2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80342 | TRAF3IP3 | LZE4T | Human | Esophagus | ESCC | 3.18e-05 | 2.28e-01 | 0.0811 |
80342 | TRAF3IP3 | LZE7T | Human | Esophagus | ESCC | 1.02e-03 | 2.62e-01 | 0.0667 |
80342 | TRAF3IP3 | LZE6T | Human | Esophagus | ESCC | 9.61e-05 | 3.07e-01 | 0.0845 |
80342 | TRAF3IP3 | P2T-E | Human | Esophagus | ESCC | 8.73e-28 | 5.02e-01 | 0.1177 |
80342 | TRAF3IP3 | P10T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.83e-01 | 0.116 |
80342 | TRAF3IP3 | P16T-E | Human | Esophagus | ESCC | 8.73e-28 | 5.60e-01 | 0.1153 |
80342 | TRAF3IP3 | P56T-E | Human | Esophagus | ESCC | 5.84e-10 | 7.33e-01 | 0.1613 |
80342 | TRAF3IP3 | P76T-E | Human | Esophagus | ESCC | 3.28e-14 | 3.72e-01 | 0.1207 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRAF3IP3 | SNV | Missense_Mutation | novel | c.1486N>T | p.Asp496Tyr | p.D496Y | Q9Y228 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
TRAF3IP3 | SNV | Missense_Mutation | c.91G>A | p.Glu31Lys | p.E31K | Q9Y228 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
TRAF3IP3 | SNV | Missense_Mutation | c.1547A>C | p.Gln516Pro | p.Q516P | Q9Y228 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
TRAF3IP3 | SNV | Missense_Mutation | c.813G>C | p.Glu271Asp | p.E271D | Q9Y228 | protein_coding | deleterious(0.03) | benign(0.03) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TRAF3IP3 | SNV | Missense_Mutation | c.1144N>A | p.Gln382Lys | p.Q382K | Q9Y228 | protein_coding | deleterious(0.02) | benign(0.378) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
TRAF3IP3 | SNV | Missense_Mutation | c.418G>C | p.Asp140His | p.D140H | Q9Y228 | protein_coding | tolerated(0.1) | benign(0.281) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
TRAF3IP3 | SNV | Missense_Mutation | novel | c.1429C>A | p.Leu477Ile | p.L477I | Q9Y228 | protein_coding | deleterious(0) | possibly_damaging(0.553) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TRAF3IP3 | SNV | Missense_Mutation | c.979N>C | p.Glu327Gln | p.E327Q | Q9Y228 | protein_coding | tolerated(0.14) | benign(0.05) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TRAF3IP3 | SNV | Missense_Mutation | c.983A>G | p.Asp328Gly | p.D328G | Q9Y228 | protein_coding | deleterious(0.04) | benign(0.053) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TRAF3IP3 | SNV | Missense_Mutation | rs759256006 | c.73N>T | p.Arg25Cys | p.R25C | Q9Y228 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |